Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients [0.03%]
多西环素不影响HIV感染患者的蛋白酶抑制剂或非核苷类反转录酶抑制剂的谷浓度
S Abgrall,J Le Bel,N Lele et al.
S Abgrall et al.
Background: Many HIV-treated patients travel to malaria-infected zones, but very few data are available on potential interactions between antiretroviral and antimalarial drugs. ...
Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications [0.03%]
评估吡格列酮和运动训练对HIV阳性代谢紊乱患者的基础心肌底物代谢和左心室功能影响的试点研究
W Todd Cade,Dominic N Reeds,E Turner Overton et al.
W Todd Cade et al.
Background: Individuals with HIV infection and peripheral metabolic complications have impaired basal myocardial insulin sensitivity that is related to left ventricular (LV) diastolic dysfunction. It is unknown whether in...
Randomized Controlled Trial
HIV clinical trials. 2013 Nov-Dec;14(6):303-12. DOI:10.1310/hct1406-303 2013
Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268 [0.03%]
非洲裔美国HIV感染妇女宫颈上皮内瘤变的遗传预测因子：ACTG DACS 268研究
Michelle S Cespedes,Sarah L Kerns,Robert S Holzman et al.
Michelle S Cespedes et al.
Objective: To examine genome-wide associations in HIV-infected women with a history of cervical dysplasia compared with HIV-infected women with no history of abnormal Papanicolaou (Pap) tests. ...
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202 [0.03%]
恩曲他滨/富马酸替诺福韦二吡呋酯与阿巴卡韦/拉米夫定的早期病毒学反应：艾滋病临床试验组A5202研究
Philip M Grant,Camlin Tierney,Chakra Budhathoki et al.
Philip M Grant et al.
Background: ACTG A5202 randomized treatment-naïve individuals to tenofovir-emtricitabine (TDF/FTC) or abacavir-lamivudine (ABC/3TC) combined with efavirenz (EFV) or atazanavir/ritonavir (ATV/r). Individuals in the high s...
Randomized Controlled Trial
HIV clinical trials. 2013 Nov-Dec;14(6):284-91. DOI:10.1310/hct1406-284 2013
Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial [0.03%]
在对丙型肝炎病毒(HCV)治疗无反应的感染人类免疫缺陷病毒(HIV)-1和HCV-1型共感染患者中，硝唑氮芥与PEG-IFN和利巴韦林联合使用改善HCV治疗效果：ACTG A5269试验结果
Valerianna K Amorosa,Anne Luetkemeyer,Minhee Kang et al.
Valerianna K Amorosa et al.
Background: We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/...
Clinical Trial
HIV clinical trials. 2013 Nov-Dec;14(6):274-83. DOI:10.1310/hct1406-274 2013
Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study [0.03%]
艾滋病病毒血清阳性者非感染性腹泻用crofelemer片疗效和安全性：一项随机双盲安慰剂对照两阶段研究
Rodger D Macarthur,Trevor N Hawkins,Stephen J Brown et al.
Rodger D Macarthur et al.
Background: HIV-associated diarrhea remains a significant concern with limited treatment options. Objective: To determine the optimal d...
Clinical Trial
HIV clinical trials. 2013 Nov-Dec;14(6):261-73. DOI:10.1310/hct1406-261 2013
Efficacy and tolerability of darunavir/ritonavir in combination with abacavir/lamivudine: an option in selected HIV-infected patients [0.03%]
达芦那韦/利托那韦与阿巴卡韦/拉米夫定联合应用的疗效和耐受性：特定HIV感染患者的治疗选择
Ignacio de los Santos,Ana Gómez-Berrocal,Eulalia Valencia et al.
Ignacio de los Santos et al.
Objective: To evaluate the safety and efficacy of abacavir/lamivudine (ABC/3TC) plus darunavir/ritonavir (DRV-RTV) in experienced patients. Methods: ...
Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384 [0.03%]
艾滋病护理启动研究：治疗依从性和转归的护士发起电话干预：艾滋病临床试验组项目384的附属研究
Gregory K Robbins,Marcia A Testa,Max Su et al.
Gregory K Robbins et al.
Background: Effective and easy to implement interventions to improve adherence to antiretroviral therapy are needed. Objective: To comp...
Randomized Controlled Trial
HIV clinical trials. 2013 Sep-Oct;14(5):235-53. DOI:10.1310/hct1405-235 2013
Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142 [0.03%]
ACTG A5142研究中随机方案及核苷类反转录酶抑制剂选择对骨矿物密度的影响
Jeannie S Huang,Michael D Hughes,Sharon A Riddler et al.
Jeannie S Huang et al.
Objective: To compare the longitudinal changes in total bone mineral density (TBMD) across antiretroviral (ARV) regimens. Methods: A514...
Clinical Trial
HIV clinical trials. 2013 Sep-Oct;14(5):224-34. DOI:10.1310/hct1405-224 2013
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens [0.03%]
从依非韦伦换用利匹韦林联合恩曲他滨/富马酸替诺福韦二吡美酯片复方单片制剂48周疗效和安全性分析
Anthony M Mills,Calvin Cohen,Edwin Dejesus et al.
Anthony M Mills et al.
Background: Due to ongoing neuropsychiatric adverse events in some efavirenz (EFV)-treated patients, a switch to an alternative non-nucleoside reverse transcriptase inhibitor may be considered. Rilpivirine (RPV) has been ...
Clinical Trial
HIV clinical trials. 2013 Sep-Oct;14(5):216-23. DOI:10.1310/hct1405-216 2013